OWLT

Owlet Announces Fourth Quarter and Fiscal Year 2023 Results

Retrieved on: 
Thursday, March 7, 2024
Apps, Applications, Mobile, Wireless, Technology, Parenting, Baby, Maternity, Specialty, Software, Consumer, Retail, Consumer Electronics, Operating cost, OWLT, FDA, Adjustment, Entrepreneurship, Babysitting, Infant, Net, FY, Cryptocurrency

Owlet , Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

Key Points: 
  • Owlet , Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
  • I’m proud of the immense progress our team has made in re-shaping the Company in 2023, and I look forward to continued successes in 2024.”
    Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2023
    Revenues for the fourth quarter of 2023 were approximately $21.0 million.
  • Adjusted EBITDA loss was approximately $0.7 million for the fourth quarter of 2023, compared to $15.2 million for the fourth quarter of 2022.
  • Net loss per share was $0.97 for the fourth quarter of 2023, compared to net loss per share of $2.43 for the fourth quarter of 2022.

Owlet Announces $9 Million Private Placement Financing

Retrieved on: 
Monday, February 26, 2024
Apps, Applications, Mobile, Wireless, Technology, Medical Devices, Parenting, Baby, Maternity, Family, General Health, Consumer, Health, FDA, OWLT, Reform Acts, Growth, Sale, Parent, Exercise, Documentation, Venture round, Infant, Risk, Security (finance)

The transaction, which involves participation from existing investors, is expected to close on February 28, 2024, subject to customary closing conditions.

Key Points: 
  • The transaction, which involves participation from existing investors, is expected to close on February 28, 2024, subject to customary closing conditions.
  • Pursuant to the terms of the definitive agreements and the closing of the private placement, Owlet will issue shares of Series B preferred stock that are convertible into approximately 1.2 million shares of common stock.
  • “As a pioneer of smart infant monitoring, Owlet has built momentum on the back of our two new FDA clearances.
  • The Company does not endorse any projections regarding future performance, results or events that may be made by third parties.

Owlet Announces Strong Preliminary Fourth Quarter 2023 Results and to Report Fourth Quarter 2023 Financial Results on March 7, 2024

Retrieved on: 
Thursday, February 22, 2024
Apps, Applications, Technology, Parenting, Children, Baby, Maternity, Family, Health, Consumer, General Health, Telephone, OWLT, FDA, Growth, Business Wire, Entrepreneurship, Adjustment, Babysitting, Access code, Infant, Amazon, Bank statement, Self storage

Owlet , Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today announces the following preliminary unaudited results for the fourth quarter 2023.

Key Points: 
  • Owlet , Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today announces the following preliminary unaudited results for the fourth quarter 2023.
  • Q4 Gross Margin is expected to be approximately 47%, up over 1,900 basis points from 27.8% year over year.
  • Q4 Net Loss is expected to be approximately $6.9 million, down 65% from $19.5 million year over year.
  • I’m proud of the immense progress our team has made in re-shaping the company in 2023.”
    The Company will report its full fourth quarter and year-end 2023 financial results after the market closes on March 7, 2024.

Owlet to Participate in Cowen’s 44th Annual Health Care Conference

Retrieved on: 
Thursday, February 22, 2024
Software, General Health, Mobile, Wireless, Professional Services, Family, Data Management, Consumer, Apps, Applications, Technology, Parenting, Children, Baby, Maternity, Health, OWLT, Infant, Conference, Webcast

Owlet, Inc. (“Owlet”) ( NYSE : OWLT), the pioneer of smart infant monitoring, today announced that it will participate in the 44th Annual Cowen Health Care Conference, taking place on March 4 – March 6, 2024 at the Marriott Copley Place in Boston, Massachusetts.

Key Points: 
  • Owlet, Inc. (“Owlet”) ( NYSE : OWLT), the pioneer of smart infant monitoring, today announced that it will participate in the 44th Annual Cowen Health Care Conference, taking place on March 4 – March 6, 2024 at the Marriott Copley Place in Boston, Massachusetts.
  • Kurt Workman, Owlet’s Co-Founder and Chief Executive Officer, and Kate Scolnick, Chief Financial Officer, are scheduled to engage in a fireside chat on Tuesday, March 5, 2024, at 2:50 p.m. Eastern Time.
  • A link to the live webcast of the fireside chat will be available on the Owlet Investor Relations website, investors.owletcare.com .
  • A replay of the webcast will also be available on Owlet’s Investor Relations website .

Owlet Transforms Infant Care with the Launch of Two FDA-Cleared Devices – Dream Sock® and BabySat™

Retrieved on: 
Monday, January 8, 2024
Women, Other Health, Parenting, Children, Telecommunications, Baby, Maternity, Software, Family, Medical Devices, Hospitals, Consumer, Data Management, Technology, Mobile, Wireless, General Health, FDA, Health, Apps, Applications, Entrepreneurship, Food, Caregiver, IOS, Mortality, Parent, Research, Babysitting, Insurance, Oxygen, Ventricular septal defect, OWLT, Sleep, Infant, Vital signs, De novo, Birth control

Owlet , Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today announces the launch and availability of Dream Sock® and BabySat™ , two medical devices with recent clearances from the U.S. Food and Drug Administration (“FDA”).

Key Points: 
  • Owlet , Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today announces the launch and availability of Dream Sock® and BabySat™ , two medical devices with recent clearances from the U.S. Food and Drug Administration (“FDA”).
  • Both innovations deliver real-time health insights with medical-grade accuracy and unprecedented advancements for at-home infant care.
  • These features are available to both existing and new Dream Sock users who opt to enable these features in the Dream App.
  • For more details on each device and to find out which product is the right choice for your family, visit www.owletcare.com .

Owlet to Participate in BTIG’s Digital Health Forum

Retrieved on: 
Tuesday, November 14, 2023
Women, General Health, Health, Parenting, Children, Family, Baby, Maternity, Consumer, NYSE, OWLT, Cryptocurrency

Owlet, Inc. (“Owlet”) ( NYSE : OWLT) today announced that it will participate in the BTIG Digital Health Forum, taking place on Monday, November 20, 2023, virtually.

Key Points: 
  • Owlet, Inc. (“Owlet”) ( NYSE : OWLT) today announced that it will participate in the BTIG Digital Health Forum, taking place on Monday, November 20, 2023, virtually.
  • Kurt Workman, Owlet’s Co-Founder and Chief Executive Officer, and Kate Scolnick, Chief Financial Officer, are scheduled to engage in a fireside chat on Monday, November 20, at 11 a.m. Eastern Time.
  • Management will also participate in 1x1 meetings which may be requested through BTIG.

Owlet Announces Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Children, Biotechnology, Baby, Maternity, Other Consumer, Health, General Health, Biometrics, Health Technology, Medical Devices, Consumer, Parenting, EBITDA, NYSE, Q2, Amazon, Babysitting, Amazon (company), Conference call, Investment, Net, FDA, Event, Conference, OWLT, Q4, Operating cost, Growth, Online shopping, Pharmaceutical industry, Video game, Owlet

Owlet, Inc. (“Owlet” or the “Company”) (NYSE:OWLT) today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Owlet, Inc. (“Owlet” or the “Company”) (NYSE:OWLT) today reported financial results for the third quarter ended September 30, 2023.
  • Operating expenses were approximately $11.2 million in the third quarter of 2023, compared to $26.4 million for the same period in 2022.
  • Adjusted EBITDA loss was approximately $5.5 million in third quarter 2023, compared to $18.4 million for the third quarter of 2022.
  • Net loss per share was $(0.84) for the third quarter of 2023, compared to $(2.42) for the third quarter of 2022.

Owlet Achieves De Novo FDA-Clearance For Dream Sock® – The First and Only Over-the-Counter, Medical Grade Pulse Oximeter Cleared for Infants

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Health, Parenting, Medical Devices, Children, Baby, Maternity, Consumer, Other Health, Laboratory, FDA, Gold, NYSE, Food, Parent, Entrepreneurship, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, De novo, Infant, Babysitting, Senior, OWLT, Caregiver, Algorithm, Charles Mullins (pediatric cardiologist), Medical device, Pharmaceutical industry, Owlet

Owlet is spearheading new standards for consumer and medical solutions, allowing caregivers to provide better care at home for their babies through access to advanced digital health technologies.

Key Points: 
  • Owlet is spearheading new standards for consumer and medical solutions, allowing caregivers to provide better care at home for their babies through access to advanced digital health technologies.
  • Owlet plans to make these new medical-grade features available to all existing and new Dream Sock users upon launch, soon to be announced.
  • These cleared features are for use with healthy infants between 1-18 months and 6 lbs to 30 lbs.
  • Parents and caregivers can learn more and sign up to receive the latest information and details on product availability at www.owletcare.com/fda-clearance .

Owlet to Report Third Quarter 2023 Financial Results on November 13, 2023

Retrieved on: 
Wednesday, November 1, 2023
General Health, Health, Parenting, Children, Baby, Maternity, Consumer Electronics, Technology, Consumer, Business Wire, OWLT, Telephone, NYSE, Access code, Owlet

Owlet, Inc. (“Owlet”) (NYSE: OWLT) will release its third quarter 2023 results after the market closes on November 13, 2023.

Key Points: 
  • Owlet, Inc. (“Owlet”) (NYSE: OWLT) will release its third quarter 2023 results after the market closes on November 13, 2023.
  • Owlet will issue a copy of the earnings release via Business Wire and include a copy on Owlet’s Investor Relations website at investors.owletcare.com .
  • Owlet’s Chief Executive Officer, Kurt Workman, and Chief Financial Officer, Kate Scolnick, will host a conference call that same day at 4:30 p.m.
  • To listen to the conference call via live audio webcast, please visit the Events section of Owlet’s Investor Relations website at investors.owletcare.com .

OWLT ALERT: Levi & Korsinsky, LLP Announces an Investigation into the Fairness of Owlet's De-SPAC Merger

Retrieved on: 
Tuesday, October 3, 2023
LLP, Person, Telephone, Levi, NYSE, OWLT, Owlet

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of Owlet's 2021 de-SPAC merger.

Key Points: 
  • You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of Owlet's 2021 de-SPAC merger.
  • Shortly after the Owlet 2021 de-SPAC merger closed, Owlet stock began spiraling downwards.
  • To learn more about the action and your rights, go to:
    or contact Joseph E. Levi, Esq.
  • Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington, D.C.